In this study, we also showed that ex vivo cultured T cells specific towards different MMAAs, either priming naïve T cells or expanding naturally occurring CD4+ and CD8+ memory T cells, were reactive against autologous MM-peptide-pulsed cell targets, thus suggesting that such specific cytotoxic T cells (CTLs) could represent an attractive immunotherapeutic option (namely, adoptive cell therapy, ACT), particularly for MGUS/SMM patients at higher risk of progression to MM. The gene discussed is CD8A; the disease is Miyoshi myopathy.